文献速递乳腺癌放疗放疗物理与技术

乳腺癌知识库计划VMAT的剂量学与毒性结局:回顾性队列分析

Dosimetry and toxicity outcomes of knowledge-based volumetric modulated arc therapy for breast cancer: A retrospective cohort analysis.
PubMed 文献 · Radiother Oncol · 2026-07-17

该单中心回顾性队列纳入2020年6月至2023年6月接受知识库计划(KBP)容积旋转调弧放疗(VMAT)的484例乳腺癌患者,前瞻性收集剂量学与毒性数据。结果显示剂量约束轻松满足国际指南,99%患者CTV原发灶D95%≥95%处方剂量,无医生报告≥3级急性毒性及肺炎。结论认为标准化KBP-VMAT技术可行、剂量学优异且急性毒性低。

要点

  • 484例乳腺癌患者接受KBP-VMAT,剂量约束轻松满足国际指南。
  • 99%患者CTV原发灶D95%≥95%处方剂量。
  • 无医生报告≥3级急性毒性,无肺炎记录。

核心结论

  • 标准化KBP-VMAT在大型真实世界队列中技术可行、剂量学优异且医生报告的急性毒性低。

研究设计与样本

  • 单中心回顾性队列分析,纳入2020年6月至2023年6月澳大利亚皇家北岸医院所有接受根治性放疗的乳腺癌患者,共484例,均采用VMAT技术及KBP计划,前瞻性收集剂量学与毒性数据。

主要发现

  • 对于单纯乳腺/胸壁患者(n=349),常规分割(SF)中位平均心脏剂量<2 Gy,大分割(HF)<1.05 Gy,超低分割(UHF)<0.7 Gy。
  • 同组患者中位平均患侧肺剂量:SF<7.7 Gy,HF<5.3 Gy,UHF<3.6 Gy。
  • 近全部患者(99%)实现CTV原发灶至少D95%≥95%处方剂量(TD)。
  • 急性毒性方面,无医生报告的≥3级毒性,无肺炎记录。

关键数值与推荐

  • 剂量约束轻松满足国际指南。
  • 99%患者CTV原发灶D95%≥95%处方剂量。
  • 无≥3级医生报告急性毒性及肺炎。

临床怎么用

  • KBP-VMAT可用于乳腺癌放疗,实现优异剂量学并降低医生报告急性毒性。

局限性

  • 回顾性、单臂设计,缺乏长期毒性结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Volumetric modulated arc therapy (VMAT) in breast radiotherapy has seen limited uptake in routine care. Barriers to adoption include concerns regarding toxicity, dosimetry and low dose wash. There is a lack of modern data to address these concerns. Therefore, the aim of this study is to report on real-world outcomes from a single-class solution implementation of VMAT planned with knowledge-based planning (KBP). METHODS: A retrospective review of all breast cancer patients undergoing definitive radiotherapy at Royal North Shore Hospital (Sydney, Australia) from June 2020 to June 2023 inclusive was undertaken. All patients were treated with a VMAT technique and planned with KBP. Prospectively collected dosimetry and toxicity data was collated. RESULTS: We identified 484 patients satisfying the inclusion criteria. Doses to constraints easily met international guidelines. For breast/chest-wall alone patients (n = 349), the median average heart dose was <2 Gy for standard fractionation (SF), <1.05 Gy for hypofractionated (HF) and <0.7 Gy for ultrahypofractionated (UHF) patients. The median average ipsilateral lung dose was <7.7 Gy for SF patients, <5.3 Gy for HF patients and <3.6 Gy for UHF patients. Nearly all patients (99%) achieved at least D95% ≥ 95% of the prescribed dose (TD) to the CTV primary. For acute toxicity, there were no clinician-reported high grade (Grade ≥ 3) toxicities and no pneumonitis recorded. CONCLUSION: This study demonstrates the technical feasibility, excellent dosimetry, and low clinician-reported acute toxicity of a standardised KBP-VMAT approach within a large, real-world cohort. Our approach easily met constraints set in recent international guidelines and randomised controlled trial protocols. While limited by its retrospective, single-arm nature and lack of long-term toxicity outcomes, this study adds to a growing body of literature on the use and outcomes of modern VMAT in breast radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chan J, Knight A, Baker L, et al. Dosimetry and toxicity outcomes of knowledge-based volumetric modulated arc therapy for breast cancer: A retrospective cohort analysis. Radiother Oncol. 2026. PMID: 42468606. doi:10.1016/j.radonc.2026.111704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。